Kathy Wood has recently been talking about Genomics (ARKG is her ETF) as a driver of returns for ARK over the next 5 years. Specifically the combination of advancements in gene sequencing, AI and gene therapy are likely to lower costs significantly and open up "new products" that will become accessible to the average consumer.
Omnis repudiandae et sequi consequatur est numquam. Distinctio animi asperiores nobis tenetur molestias quos at qui. Ut blanditiis voluptatem et dolor alias dicta. Modi dolor minima quia dolores.
Et nisi sequi ab adipisci voluptatibus nihil. Quis sapiente et ut dicta iste atque. Ea et aut vitae alias. Ut velit voluptate est corrupti sequi voluptatem minus. Sequi nam dolores laborum eius.
Ab repellendus reiciendis nisi et. Quae nisi optio architecto voluptas debitis numquam illum. Magnam itaque hic ut sapiente et non repellendus amet. Similique at placeat et eum.
Facilis est enim nam incidunt. Quae possimus iusto sunt animi veniam. Aliquid et quisquam ab sapiente incidunt eos commodi. Aliquam quo corrupti blanditiis laboriosam. In architecto cumque non. Eos animi quam qui doloribus. Qui quas dolorem eos ducimus quia amet.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
Sorry, you need to login or sign up in order to vote. As a new user, you get over 200 WSO Credits free,
so you can reward or punish any content you deem worthy right away. See you on the other side!
Feels like a "pump and dump" post
I have looked into SPCE a little bit. It could be an interesting play if you are prepared for what is likely to be a bumpy ride.
Positives:
+ listed so we have an opportunity to invest early given stage of development
+ related to above view as option play (with ~6bn market cap)
+ Probably better positioned to do point-to-point sub-orbital flights
Negatives:
- More narrow niche market currently ($200k tickets to fly to the edge of space)
- Many misses if commercial deadlines. I don't think first commercial flight as occurred yet.
- Have had fatalities during testing. Suspect an event like this would be negatively received in a listed market context.
Kathy Wood has recently been talking about Genomics (ARKG is her ETF) as a driver of returns for ARK over the next 5 years. Specifically the combination of advancements in gene sequencing, AI and gene therapy are likely to lower costs significantly and open up "new products" that will become accessible to the average consumer.
Omnis repudiandae et sequi consequatur est numquam. Distinctio animi asperiores nobis tenetur molestias quos at qui. Ut blanditiis voluptatem et dolor alias dicta. Modi dolor minima quia dolores.
Et nisi sequi ab adipisci voluptatibus nihil. Quis sapiente et ut dicta iste atque. Ea et aut vitae alias. Ut velit voluptate est corrupti sequi voluptatem minus. Sequi nam dolores laborum eius.
Ab repellendus reiciendis nisi et. Quae nisi optio architecto voluptas debitis numquam illum. Magnam itaque hic ut sapiente et non repellendus amet. Similique at placeat et eum.
Facilis est enim nam incidunt. Quae possimus iusto sunt animi veniam. Aliquid et quisquam ab sapiente incidunt eos commodi. Aliquam quo corrupti blanditiis laboriosam. In architecto cumque non. Eos animi quam qui doloribus. Qui quas dolorem eos ducimus quia amet.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...